Q2 FY2026 EarningsQ2 FY2026 results showed a top-line beat with revenue of $9.6M vs. $9.3M consensus, while GAAP EPS missed expectations at -$0.07 vs. -$0.04 due to significant non-cash foreign exchange losses. Gross margin was slightly below consensus at 73.2% vs. 73.5% expected, despite showing sequential improvement. Strong 16% growth in distributor territories was offset by a 24% decline in Germany following sales force restructuring, though management remains on track for operating cash flow breakeven in H2 2026.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: CytoSorbents(CTSO) the Revenue is 9.633 M (+0.17%), Beat estimate;the EBIT is -2.638 M (+27.03%), Miss estimate;the EPS is -0.07 (-333.3%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.01B0.17%
0.01B2.82%
+0.00B2.99%
EBITMiss expectations
-0.00B27.03%
-0.00B33.72%
-0.00B6.69%
EPSMiss expectations
-0.07333.33%
-0.0433244.43%
-0.026788.90%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf